Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)

NCT02437396 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT02437396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02437396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)
Lead sponsor
University of Minnesota
Phase
Observational
Overall status
Recruiting
Start date
October 31, 2015
Completion date
October 30, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease type i, inflammation, oxidative stress